BPI East Boston: Tracy & Sophie Ryan's Plenary Keynote

Carlsbad, CA – October 2025 — NKore BioTherapeutics and its Co-Founder & Chief Communications Officer, Tracy Ryan, have been recognized with the Impact Award at the prestigious Global Capital Network (GCN) Investor Conference for their groundbreaking work in developing non-toxic, Natural Killer (NK) cell therapies aimed at treating terminal and incurable cancers. The award celebrates companies that are creating measurable, life-changing impact across industries — and few stories embody that mission more powerfully than NKore’s. Founded out of a mother’s determination to save her child, NKore’s journey began when Tracy Ryan’s daughter, Sophie, was diagnosed with a rare and aggressive brain tumor as a baby. Refusing to accept traditional limits, Ryan partnered with scientists and clinicians to pioneer a revolutionary approach to cancer treatment — one that harnesses the body’s own immune system through supercharged NK cells. Today, Sophie — now Patient #2 in NKore’s early human studies — represents both the inspiration and proof-of-concept behind the company’s technology. NKore’s proprietary NK101 cell platform has shown promising results in patients with aggressive, treatment-resistant cancers, providing new hope where conventional therapies have failed with Sophie's most recent scan showing crumbling in her incurable tumor. “Receiving the Impact Award is deeply personal for us,” said Tracy Ryan, following the ceremony. “NKore was born from love, desperation, and an unwavering belief that science could offer something better — not just for my daughter, but for every family told there are no options left. This award validates the impact we’re already making and the future we’re building.” The event, held in Carlsbad, CA, brought together investors, innovators, and thought leaders from across the biotech, healthcare, and technology sectors. NKore’s participation was marked not only by Ryan’s powerful on-stage pitch but also by her dynamic presence as Master of Ceremonies during the conference’s second half — a testament to her ability to connect scientific innovation with human purpose. Under Ryan’s leadership and alongside CEO Dr. Aaron U. Levy, NKore continues to advance its NK cell therapy pipeline toward clinical readiness, with a focus on solid tumors and other immune-related diseases. The company’s mission — “From Immune Anarchy to Precision Healing” — reflects its vision of restoring balance within the immune system through next-generation, off-the-shelf NK cell treatments. As NKore moves toward broader clinical trials and global partnerships, this Impact Award serves as both recognition of its achievements and motivation to continue pushing the boundaries of what’s possible in cancer immunotherapy.

We’re thrilled to announce that Tracy Ryan and her daughter Sophie Ryan will be the plenary keynote speakers at the PDA Southern California Chapter Cell Therapy Manufacturing: Emerging Trends event, taking place on Thursday, August 7, 2025 , at The Grand , Long Beach, CA . 🎤 About Our Speakers Tracy Ryan Co‑Founder and Chief Communications Officer of NKore BioTherapeutics, Tracy brings a compelling first‑hand perspective as a patient turned entrepreneur. Her keynote will illuminate the human impact and promise of cell therapy in transforming cancer care. Sophie Ryan Joining her mother on stage, Sophie brings a personal and deeply moving narrative of resilience, hope, and forward‑looking innovation—a powerful complement to Tracy’s story. Together, they offer a unique blend of scientific insight and lived experience , bridging the clinical and personal sides of cell therapy’s emergence. 💡 Why You Should Attend Gain insider perspectives on emerging trends in cell therapy manufacturing , including scale‑up, regulatory pathways, and innovation in NK-based immunotherapies. Hear firsthand from leading voices in biotech entrepreneurship and patient‑driven innovation. Connect with industry professionals, researchers, and decision‑makers shaping the future of cell therapies. 🎟️ Get Your Tickets Don’t miss this opportunity to learn from two exceptional speakers at the forefront of cancer immunotherapy. Reserve your spot now here: Get Tickets for PDA SoCal — August 7, Long Beach

At this year’s Innate Killer Summit in San Diego , one of the most powerful and lasting impressions came from the work and wisdom of our beloved scientific founder, Dr. Anahid Jewett . Dr. Jewett, a pioneering immunologist and globally recognized NK cell expert, gave what would become some of her final public presentations—leaving an unforgettable mark on the international community of innate immune researchers and biotech leaders. Her talks, delivered with characteristic brilliance and humility, distilled decades of research into a clear, compelling vision: that natural killer cells are the future of cancer therapy , and that future is already within reach. Her presentations spanned the arc of her life’s work—from her early discoveries in NK cell cytotoxicity and tumor immune evasion, to the breakthrough techniques she developed to “supercharge” NK cells for clinical use. She walked the audience through the translational path from lab bench to bedside, showing data from patient studies that support the promise of non-toxic, precision immunotherapy for some of the most treatment-resistant cancers. But what made her presence at BPI’s Innate Killer Summit so deeply moving was not just the science—it was her spirit. Her commitment to patients, her fierce intellect, and her belief in the power of immune-based healing came through in every word. The response from the audience was overwhelming. Researchers, physicians, and investors alike approached our team throughout the week to express their gratitude for her work and their admiration for her clarity of vision. One attendee called her “the North Star of NK cell science.” We couldn’t agree more. As a company, NKore BioTherapeutics has been built on the foundation of Dr. Jewett’s groundbreaking research. And though she is no longer with us physically, she has left behind something far more powerful: a blueprint for innovation, a roadmap for clinical success, and an unshakable commitment to saving lives . We are proud to carry forward her legacy. We are advancing the very therapies she envisioned, treating patients who once had no options, and moving closer every day to an era where cancer can be treated effectively and gently—through the body’s own immune defenses. Thank you, Dr. Jewett, for everything. You’ve given the world more than it knows, and we will never stop building the future you helped us see.

At this year’s BioProcess International U.S. West (BPI West) conference in San Diego, Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, delivered a powerful plenary keynote that resonated deeply with attendees. The keynote wove together a deeply personal origin story with a compelling scientific roadmap for NKore’s flagship therapy, NK101, an off-the-shelf natural killer (NK) cell immunotherapy platform. From Personal Tragedy to Scientific Breakthrough Ryan opened her address with the emotional account of her daughter Sophie’s diagnosis with a brain tumor at just eight and a half months old. This life-altering event became the catalyst for founding NKore, in collaboration with Dr. Anahid Jewett of UCLA, with the goal of advancing safer, more effective immunotherapies—especially for children facing aggressive cancers. NK101: A Next-Generation NK Cell Therapy During the keynote, Ryan introduced NK101, NKore’s allogeneic NK cell product designed to be potent, non-toxic, and ready-to-use. The company’s preclinical data show promising safety and efficacy, and NK101 is on track to enter U.S. clinical trials in 2026. The announcement generated enthusiastic feedback from investors, scientists, and biopharma leaders alike, signaling strong momentum for NKore’s platform. Reflections from the Conference Floor Ryan’s presentation aligned closely with BPI West’s broader themes around innovation in advanced biologics manufacturing. Industry leaders like Amy Shaw of Takeda emphasized the importance of early-stage design and scalable automation for cell therapy manufacturing—principles that NKore has embraced from the outset. Other conference highlights included forward-looking panels on AI-driven optimization, digital twin technology, and the industrialization of allogeneic platforms, underscoring the sector’s commitment to turning complex cell therapies into reproducible, commercial-grade products. A Vision for the Future The energy at BPI West 2025 reflected a pivotal moment in NK cell therapy development. NKore BioTherapeutics is now moving from vision to validation, bringing NK101 to the clinic in pursuit of safe, non-toxic, and scalable solutions for cancer patients. Learn More Bioprocess Online featured coverage of the event, including insights from Ryan’s keynote. Read the full article here.

At this year’s Innate Killer Summit in San Diego, one moment stood out among the many brilliant talks and groundbreaking discoveries—a plenary keynote that brought the room to its feet not once, but twice. That keynote was ours. Sharing the stage with my daughter—who has battled brain cancer her entire life—was one of the most profound honors of my life. Together, we shared not just a personal journey through the darkest days of pediatric cancer, but a story of scientific resolve, patient courage, and the incredible promise of NK (natural killer) cell therapy. Our presentation, which opened Day 2 of the Summit, chronicled the birth of NKore BioTherapeutics, the company we founded to develop non-toxic, supercharged NK cell therapies for cancer and immune-related diseases. We spoke candidly about the devastating diagnosis my daughter received at just 8 1/2 months old, the years of failed treatments, and the ultimate turning point—an experimental NK cell infusion that marked a turning point in her recovery. The room was silent as we walked through the science: how our NK cells are engineered to work smarter, last longer, and target tumors without harming healthy tissue. But what made the biggest impact wasn’t just the data—it was my daughter walking on stage herself, full of life and spirit, to share her voice. The first standing ovation came after her speech. The second came at the end, when we declared our mission loud and clear: We will not stop until every patient has access to the same kind of hope. We left the stage overwhelmed with emotion, gratitude, and even greater resolve. The support we received from leading researchers, clinicians, and investors reminded us that the tide is turning in cancer care. The future isn’t just coming—it’s already being built, and it’s being built by people who believe that the immune system, when properly supported, can do what once seemed impossible. Thank you to the organizers of the Innate Killer Summit, to the community that welcomed our story, and to every patient and family who continues to inspire our work. This was more than a keynote. It was a call to action. We heard you. And we’re just getting started.

NKore's Chief Communications Officer has proudly served as a dedicated member of the prestigious, invitation-only marketing organization, PTTOW, for an impressive nine years. This distinguished group focuses on fostering connections among the top marketing executives from some of the largest and most influential brands in the world. As a regularly invited speaker at their events, Tracy draws upon her nearly 40 years of marketing expertise, complemented by her extensive experience in building successful companies. Beyond her professional accomplishments, Tracy offers a unique and deeply personal perspective on patient care, informed by her enduring role as the mother of a cancer survivor. She provides attendees with an insightful and heartfelt look at how she transformed a life-altering tragedy into a story of resilience and triumph. Her own child's battle with a relentless form of cancer that ravaged her brain for nearly seven years serves as a powerful testament to the strength of the human spirit, inspiring others to find hope and healing in the face of life's greatest challenges.

NKore BioTherapeutics is proud to announce that Dr. Anahid Jewett, renowned immunotherapy cancer research scientist, has been honored with the distinguished recognition of being named one of the top 2% of scientists in the world by Stanford University. This prestigious accolade is a testament to Dr. Jewett's exceptional contributions to the field of natural killer (NK) cell therapy for cancer.

Our CoFounder and Chief Communications Officer Tracy Ryan had the incredible honor and privilege of being invited back to the White House for the 4th time in just a span of 12 months!

On-Location Long Beach, California On this episode of Let's Be Blunt, Montel meets up with Tracy Ryan and Dr. Anahid Jewett at this year's Cannabis Science Conference. Tracy Ryan - a returning guest - has a daughter named Sophie who was diagnosed with a brain tumor at 8 1/2 months old (she’s now 9 years old). Dr. Anahid is a respected immunologist and professor at UCLA School of Dentistry who has been studying natural killer cells for over thirty years. She has made numerous groundbreaking discoveries related to both cancer and ALS. Tracy connected with Dr. Jewett and they started treating Sophie as the first-ever natural killer cell treatment patient. If this treatment continues to be successful, it could become an incredible alternative treatment option for cancer patients.